Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. Small EJ, et al. Among authors: ando d. Mol Ther. 2006 Jul;14(1):107-17. doi: 10.1016/j.ymthe.2006.02.011. Epub 2006 May 9. Mol Ther. 2006. PMID: 16690359 Free article. Clinical Trial.
Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. Simons JW, et al. Among authors: ando dg. Cancer Res. 1999 Oct 15;59(20):5160-8. Cancer Res. 1999. PMID: 10537292 Clinical Trial.
Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF. Nelson WG, et al. Among authors: ando dg. Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72. doi: 10.1007/pl00014053. Cancer Chemother Pharmacol. 2000. PMID: 10950151 Clinical Trial.
Advanced renal cell carcinoma treated with granulocyte-macrophage colony-stimulating factor gene therapy: a clinical course of the first Japanese experience.
Kawai K, Tani K, Yamashita N, Tomikawa S, Eriguchi M, Fujime M, Okumura K, Kakizoe T, Clift S, Ando D, Mulligan R, Yamauchi A, Noguchi M, Asano S, Akaza H. Kawai K, et al. Among authors: ando d. Int J Urol. 2002 Aug;9(8):462-6. doi: 10.1046/j.1442-2042.2002.00493.x. Int J Urol. 2002. PMID: 12225344 Free article.
Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma.
Nemunaitis J, Bohart C, Fong T, Meyer W, Edelman G, Paulson RS, Orr D, Jain V, O'Brien J, Kuhn J, Kowal KJ, Burkeholder S, Bruce J, Ognoskie N, Wynne D, Martineau D, Ando D. Nemunaitis J, et al. Among authors: ando d. Cancer Gene Ther. 1998 Sep-Oct;5(5):292-300. Cancer Gene Ther. 1998. PMID: 9824048 Clinical Trial.
186 results